Nathaniel David
Nathaniel David | |
|---|---|
 | |
| Born | San Francisco, California, U.S. |
| Nationality | American |
| Alma mater | Harvard University, University of California, Berkeley |
| Known for | Kythera Biopharmaceuticals, Kybella, Jupiter Bioventures |
| Awards | MIT Technology Review Young Innovators Under 35 |
| Scientific career | |
| Fields | Biotechnology |
| Institutions | Kythera Biopharmaceuticals, Unity Biotechnology, Jupiter Bioventures |
Nathaniel David is an American scientist and biotechnology entrepreneur who has co-founded several life sciences companies that together have raised more than $1.5 billion in financing and contributed to the development of multiple FDA-approved medicines, including alogliptin, trelagliptin, Zemiglo (Zemdi), Zemdri, and Kybella.
Biography
[edit]Education and Career
[edit]David earned an A.B. in Biology from Harvard University and a Ph.D. in Molecular and Cellular Biology from University of California, Berkeley.[1] While completing his doctorate, he co-founded Syrrx in 1999. The company developed a high-throughput structural biology platform that used automation and miniaturization to accelerate protein structure determination.[2][3] David was named to the MIT Technology Review TR35, a list of top global innovators under the age of 35. Syrrx was acquired by Takeda Pharmaceutical Company in 2005, and its research contributed to the development of Nesina (alogliptin), a diabetes drug approved by the FDA.[4][5]
David later co-founded Achaogen (NASDAQ: AKAO), focused on developing treatments for antibiotic-resistant infections. Achaogen developed Zemdri (plazomicin), which was approved by the FDA for complicated urinary tract infections.
In 2005, David co-founded Kythera Biopharmaceticals (NASDAQ: KYTH), where he served as Chief Science Officer. The company developed Kybella, the first FDA-approved injectable drug for reducing submental fat.[6] Kythera went public in 2012 and was acquired by Allergan in 2015 for $2.1 billion.[7][8]
In 2011, he also co-founded UNITY Biotechnology (NASDAQ: UBX).[9][10][11][12][13]
Recent Work
[edit]In 2021, David co-founded Jupiter Bioventures with former National Cancer Institute director Ned Sharpless. Jupiter Bioventures is a venture foundry that supports the development of therapeutic companies based on emerging biological science. It launched with an initial fund of $70 million and focuses on areas such as oncology and immunology.
References
- ^ "Biotech on brink of breakthroughs". SFGate. 22 February 2004. Retrieved 2016-03-09.
- ^ Pollack, Andrew (2000-07-04). "Analyzing Proteins With X-Rays, Crystals and Some Luck". The New York Times. ISSN 0362-4331. Retrieved 2016-03-09.
- ^ Pollack, Andrew (2000-07-04). "The Next Chapter in the Book of Life Is Written in the Proteins". The New York Times. ISSN 0362-4331. Retrieved 2016-03-09.
- ^ Pollack, Andrew (2005-04-20). "Some in Biotech Prefer an Acquisition to an I.P.O." The New York Times. ISSN 0362-4331. Retrieved 2016-03-09.
- ^ Parsa, Kishore Vl; Pal, Manojit (2011-08-01). "Preclinical development of dipeptidyl peptidase IV inhibitor alogliptin: a brief overview". Expert Opinion on Drug Discovery. 6 (8): 855–869. doi:10.1517/17460441.2011.588695. ISSN 1746-045X. PMID 22651127. S2CID 24271265.
- ^ "FDA approves treatment for fat below the chin" (Press release). U.S. Food and Drug Administration. April 29, 2015. Archived from the original on 2015-05-01. Retrieved 2016-03-09.
- ^ Sachetta, Ryan. "Allergan to Buy Kythera Biopharmaceuticals for $2.1 Billion". Bloomberg.com. Retrieved 2016-03-09.
- ^ "Top 10 biotech IPOs of 2012". FierceBiotech. Retrieved 2016-03-09.
- ^ "Backed by a lineup of marquee VCs, Unity Biotechnology tackles the hard science of aging". FierceBiotech. Retrieved 2016-03-09.
- ^ "Unity SEC S-1 Form". April 5, 2018. Retrieved 2018-11-14 – via sec.gov.
- ^ "Mayo Clinic Taps Silicon Valley to Help People Age Gracefully". Fortune. Retrieved 2016-03-09.
- ^ Yong, Ed (3 February 2016). "Clearing the Body's Retired Cells Slows Aging and Extends Life". The Atlantic. Retrieved 2016-03-09.
- ^ "Boosting Life Span By Clearing Out Cellular Clutter". NPR.org. Retrieved 2016-03-09.